These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The Roles of miR-26, miR-29, and miR-203 in the Silencing of the Epigenetic Machinery during Melanocyte Transformation. Gasque Schoof CR; Izzotti A; Jasiulionis MG; Vasques Ldos R Biomed Res Int; 2015; 2015():634749. PubMed ID: 26618174 [TBL] [Abstract][Full Text] [Related]
5. ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Luo Y; Dallaglio K; Chen Y; Robinson WA; Robinson SE; McCarter MD; Wang J; Gonzalez R; Thompson DC; Norris DA; Roop DR; Vasiliou V; Fujita M Stem Cells; 2012 Oct; 30(10):2100-13. PubMed ID: 22887839 [TBL] [Abstract][Full Text] [Related]
6. Citral reduces breast tumor growth by inhibiting the cancer stem cell marker ALDH1A3. Thomas ML; de Antueno R; Coyle KM; Sultan M; Cruickshank BM; Giacomantonio MA; Giacomantonio CA; Duncan R; Marcato P Mol Oncol; 2016 Nov; 10(9):1485-1496. PubMed ID: 27592281 [TBL] [Abstract][Full Text] [Related]
7. Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes. Samson JM; Ravindran Menon D; Smith DE; Baird E; Kitano T; Gao D; Tan AC; Fujita M Chem Biol Interact; 2019 Dec; 314():108822. PubMed ID: 31580832 [TBL] [Abstract][Full Text] [Related]
8. Lunasin is a novel therapeutic agent for targeting melanoma cancer stem cells. Shidal C; Al-Rayyan N; Yaddanapudi K; Davis KR Oncotarget; 2016 Dec; 7(51):84128-84141. PubMed ID: 27566591 [TBL] [Abstract][Full Text] [Related]
9. The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation. Maurus K; Hufnagel A; Geiger F; Graf S; Berking C; Heinemann A; Paschen A; Kneitz S; Stigloher C; Geissinger E; Otto C; Bosserhoff A; Schartl M; Meierjohann S Oncogene; 2017 Sep; 36(36):5110-5121. PubMed ID: 28481878 [TBL] [Abstract][Full Text] [Related]
10. Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma. Yue L; Huang ZM; Fong S; Leong S; Jakowatz JG; Charruyer-Reinwald A; Wei M; Ghadially R Melanoma Res; 2015 Apr; 25(2):138-48. PubMed ID: 25643237 [TBL] [Abstract][Full Text] [Related]
16. Identification of DNA repair gene Ercc1 as a novel target in melanoma. Song L; Ritchie AM; McNeil EM; Li W; Melton DW Pigment Cell Melanoma Res; 2011 Oct; 24(5):966-71. PubMed ID: 21722328 [TBL] [Abstract][Full Text] [Related]
17. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma. McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor. Wang Y; Liu M; Jin Y; Jiang S; Pan J Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241 [TBL] [Abstract][Full Text] [Related]
19. Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment. Seftor EA; Brown KM; Chin L; Kirschmann DA; Wheaton WW; Protopopov A; Feng B; Balagurunathan Y; Trent JM; Nickoloff BJ; Seftor RE; Hendrix MJ Cancer Res; 2005 Nov; 65(22):10164-9. PubMed ID: 16288000 [TBL] [Abstract][Full Text] [Related]
20. Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin. Bonchak JG; Eby JM; Willenborg KA; Chrobak D; Henning SW; Krzywiec A; Johnson SL; Le Poole IC Arch Biochem Biophys; 2014 Dec; 563():71-8. PubMed ID: 25132642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]